Nantahala Capital Management, LLC 13D and 13G filings for Soleno Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:51 pm Purchase |
2023-12-31 | 13G | Soleno Therapeutics, Inc. SLNO |
Nantahala Capital Management, LLC | 3,068,031 9.900% |
2,229,497 (+265.88%) |
Filing |
| 2023-02-14 5:06 pm Purchase |
2022-12-31 | 13G | Soleno Therapeutics, Inc. SLNO |
Nantahala Capital Management, LLC | 838,534 9.900% |
187,525 (+28.81%) |
Filing |
| 2022-02-14 08:22 am Unchanged |
2021-12-31 | 13G | Soleno Therapeutics, Inc. SLNO |
Nantahala Capital Management, LLC | 651,009 12.200% |
0 (Unchanged) |
Filing |
| 2021-07-12 4:01 pm Purchase |
2021-06-30 | 13G | Soleno Therapeutics, Inc. SLNO |
Nantahala Capital Management, LLC | 651,009 12.200% |
126,252 (+24.06%) |
Filing |
| 2021-02-12 3:22 pm Purchase |
2020-12-31 | 13G | Soleno Therapeutics, Inc. SLNO |
Nantahala Capital Management, LLC | 524,757 9.900% |
239,562 (+84.00%) |
Filing |